Skip to main content

Advertisement

SpringerLink
Log in

Screening of Metabolic-Associated Fatty Liver Disease in General Population Attending Outpatient Clinic

  • Original Paper
  • Published:
SN Comprehensive Clinical Medicine Aims and scope Submit manuscript

Abstract

Nowadays, changes of lifestyle have been associated with a dramatic increase in the prevalence of obesity. Metabolic-associated fatty liver disease (MAFLD) is a growing global health problem. To determine prevalence of MAFLD among general population, attending the out patients clinics of Beni-Suef University hospital, without history of alcohol intake, chronic liver disease, viral hepatitis infection, DM or HTN, and the efficacy of other hepatic steatosis indices in its detection. The studied subjects were classified according to MAFLD criteria. CBC, AST, ALT, creatinine, fasting blood glucose (HbA1c), lipid profile (cholesterol triglyceride), HOMA-IR, high-sensitive CRP, imaging with abdominal ultrasound, ARFI, and TE (FibroScan and CAP) were done to all subjects. Also, HS index and FAST Score were done. Efficacy of these data was assessed as predictors of MAFLD. From 588 participant, 165 patients (28.1%) had positive MAFLD criteria. FibroScan, CAP, ARFI, and FAST score were higher among the MAFLD group but without statistical significance, while HBA1c, hepatic ultrasound finding, and (HS Index) showed a statistically significant difference between groups. HSI could predict steatosis at a cutoff 39.1405 with 61% sensitivity and 71% specificity. MAFLD is common in general population. HS index is simple to calculate and can help physicians to screen patients who need follow-up for early detection of liver steatosis and lifestyle counseling.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

All data is available. Please contact author for data requests.

Code Availability

Available.

References

  1. EASL (European Association for the Study of the Liver). Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.

  2. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328–57.

    Article  PubMed  Google Scholar 

  3. Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Transplantation. 2019;103:22–7.

    Article  PubMed  Google Scholar 

  4. Buzzetti E, Pinzani M, Tsochatzis EA, et al. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038–48.

    Article  CAS  PubMed  Google Scholar 

  5. Estes C, Razavi H, Loomba R, Younossi ZM, Sanyal AJ, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–33.

    Article  CAS  PubMed  Google Scholar 

  6. Neuschwander-Tetri BA, Caldwell SH, et al. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202–19.

    Article  PubMed  Google Scholar 

  7. Zimmet P, Alberti KGMM, Shaw J, et al. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.

    Article  CAS  PubMed  ADS  Google Scholar 

  8. Gastaldelli A, Harrison S, Belfort-Aguilar R, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology. 2009;50(4):1087–93.

    Article  CAS  PubMed  Google Scholar 

  9. Fouad Y, Waked I, Bollipo S, Ahmed G, Youssef A, Attia D, et al. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD.’ Liver Int. 2020;40(6):1254–61.

    Article  PubMed  Google Scholar 

  10. Eslam M, Sarin S, Wong V, Jian-Gao F, Takumi K, Sang H, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(3):1511–20.

    Google Scholar 

  11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.

    Article  CAS  PubMed  Google Scholar 

  12. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–8 ([CrossRef)).

    Article  CAS  PubMed  Google Scholar 

  13. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102(12):2708±15. https://doi.org/10.1111/j.1572-0241.2007.01526.x.

    Article  Google Scholar 

  14. Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C, et al. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology. 2012;56:2125.

    Article  PubMed  Google Scholar 

  15. Fierbinteanu-Braticevici C, Andronescu D, Usvat R, Cretoiu D, Baicus C, Marinoschi G, et al. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis. World J Gastroenterol WJG. 2009;15(44):5525.

    Article  PubMed  Google Scholar 

  16. Gaia S, Carenzi S, Barilli AL, et al. Reliability of transient elastography for the detection of fibrosis in nonalcoholic fatty liver disease and chronic viral hepatitis. J Hepatol. 2011;54:64–71. https://doi.org/10.1016/j.jhep.2010.06.022.

    Article  PubMed  Google Scholar 

  17. Kamali L, Adibi A, Ebrahimian S, Jafari F, Sharifi M, et al. Diagnostic performance of ultrasonography in detecting fatty liver disease in comparison with Fibroscan in people suspected of fatty liver. Adv Biomed Res. 2019;8:69. https://doi.org/10.4103/abr.abr_114_19.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362–73. www.thelancet.com/gastrohep.

  19. Eslam M, Newsome P, Sarin S, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–9. https://doi.org/10.1016/j.jhep.2020.03.039.

    Article  PubMed  Google Scholar 

  20. Yuan Q, HuaiWang PG, Chen W, Lv M, Bai S, Jiang Wu, et al. Prevalence and Risk Factors Of Metabolic-Associated Fatty Liver Disease among 73,566 individuals in Beijing. China. 2022. https://doi.org/10.3390/ijerph19042096Int.J.Environ.Res.PublicHealth,19,2096.

    Article  Google Scholar 

  21. Chen Y-L, Li H, Li S, Xu Z, Tian S, Wu J, Liang X-Y, Li X, Liu Z-L, Xiao J, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21:212 [CrossRef] [PubMed].

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Feng R-N, Du S-S, Wang C, Li Y-C, Liu L-Y, Guo F-C, Sun C-H, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20:17932–40 [CrossRef] [PubMed].

    Article  PubMed  PubMed Central  Google Scholar 

  23. Semmler G, Wernly S, Bachmayer S, Wernly B, Schwenoha L, Huber-Schönauer U, Stickel F, Niederseer D, Aigner E, Datz C, et al. Nonalcoholic fatty liver disease in lean subjects: associations with metabolic dysregulation and cardiovascular risk—a single-center cross-sectional study. Clin Transl Gastroenterol. 2021;12:e00326 ([CrossRef] [PubMed]).

    Article  PubMed  PubMed Central  Google Scholar 

  24. Han AL,  Lee HK. Comparison of the diagnostic performance of steatosis indices for discrimination of CT-diagnosed metabolic dysfunction-associated fatty liver disease. Metabolite. 2022;12(7):664. https://doi.org/10.3390/metabo12070664.

  25. Cicero AF, D’Addato S, Reggi A, Reggiani GM, Borghi C. Hepatic steatosis index and lipid accumulation product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study. Intern Emerg Med. 2013;8(3):265–7. https://doi.org/10.1007/s11739-012-0875-9.

    Article  PubMed  Google Scholar 

  26. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuationparameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825±35. https://doi.org/10.1016/j.ultrasmedbio.2010.07.005.

    Article  Google Scholar 

  27. Li YY, Wang XM, Zhang YX, Ou G-C, et al. Ultrasonic elastography in clinical quantitative assessment of fatty liver. World J Gastroenterol. 2010;16(37):4733–7.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Varsha PR, Priya RB, Sarang SG, Sarang RR, et al. Correlation of ultrasound acoustic radiation force impulse elastography with sonographic severity grading of fatty liver disease. J Clin Diagn Res. 2018;12:9 (TC09-TC12).

    Google Scholar 

  29. de Azevedo Salgado ALF, de Carvalho L, Oliveira AC, dos Santos VN, Vieira JG, Parise ER, et al. Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. J Arq Gastroenterol. 2010;47:2.

    Google Scholar 

  30. Bruserud Ø, Vo AK, Rekvam H. Hematopoiesis, inflammation and aging-the biological background and clinical impact of anemia and increased C-reactive protein levels on elderly individuals. J Clin Med. 2022;11(3):706. https://doi.org/10.3390/jcm11030706.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Huang J, Wang M, Wu Y, Kumar R, Lin S, et al. Serum high sensitive c-reactive protein is a simple indicator for all cause among individual with MAFLD. J Front Physiol. 2022;13. https://doi.org/10.3389/fphys.2022.1012887.

  32. Mahale AR, Prabhu SD, Nachiappan M, Fernandes M, Ullal S, et al. Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups. J Int Med Res. 2018;46(11):4447–54.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Eletreby R, Abdellatif Z, Gaber Y, Ramadan A, Ahmad N, Khattab H, Said M, Saad Y, et al. Validity of routine biochemical and ultrasound scores for prediction of hepatic fibrosis and steatosis in NAFLD. Egypt Liver J. 2021;11:44. https://doi.org/10.1186/s43066-021-00115-6.

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Hepatology, Gastroenterology and Infectious Diseases, Beni-Suef University, Beni-Suef, Egypt

    Asmaa S. Sieddek & Dina Attia

  2. Community Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt

    Raghda Refaie Muhammed

Authors
  1. Asmaa S. Sieddek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raghda Refaie Muhammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dina Attia
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

A.S.S.: put the study design, manuscript preparation, and editing; R.R.M.: collected and analyzed the data; D.I.A.: helped in study design, helped in data analysis, reviewed the manuscript; all authors have critically reviewed and approved the final draft and are responsible for the content and similarity index of the manuscript.

Corresponding author

Correspondence to Asmaa S. Sieddek.

Ethics declarations

Ethics Approval

Ethics approval by Research Ethical Committee, faculty of Medicine, Beni-Suef University, FWA#:FWA00015574, Approval No; FMBSUREC/07032021/sieddek. Informed consent obtained from patients to participate in the study.

Consent for Publications

Approved for publications. Not applicable as no individual data, images, or were included in the study.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Medicine

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sieddek, A.S., Muhammed, R.R. & Attia, D. Screening of Metabolic-Associated Fatty Liver Disease in General Population Attending Outpatient Clinic. SN Compr. Clin. Med. 6, 18 (2024). https://doi.org/10.1007/s42399-023-01628-4

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s42399-023-01628-4

Keywords

Search

Navigation